Received Feb 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | ET475 | — |
Vaccine exposure during pregnancy; This non-serious prospective pregnancy case was reported by a nurse and described the occurrence of vaccine exposure during pregnancy in a 35-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number ET475) for prophylaxis. On 23-MAY-2024, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced vaccine exposure during pregnancy (Verbatim: Vaccine exposure during pregnancy). The outcome of the vaccine exposure during pregnancy was unknown. Pregnancy exposure: Gestation time at first exposure (Boostrix): 30 Weeks Pregnancy Exposure (Boostrix): To mother in third trimester Estimated Delivery/Due date: 07-AUG-2024 Pregnancy Details (Neonate 1): Number of Fetuses/Neonates: 1 Pregnancy Outcome: Pregnancy was ongoing Additional Information: GSK receipt date: 23-MAY-2024 The Nurse reported that a patient received Boostrix vaccine during pregnancy, which led to vaccine exposure during pregnancy. The reporter consented to follow up. Upon internal review the case was updated on 10-FEB-2025 The report type was updated from PMS to Spontaneous. Summary of changes: Report type, product details and narrative were updated.